<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Lab Physicians</journal-id><journal-id journal-id-type="iso-abbrev">J Lab Physicians</journal-id><journal-id journal-id-type="publisher-id">JLP</journal-id><journal-title-group><journal-title>Journal of Laboratory Physicians</journal-title></journal-title-group><issn pub-type="ppub">0974-2727</issn><issn pub-type="epub">0974-7826</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3574494</article-id><article-id pub-id-type="publisher-id">JLP-4-101</article-id><article-id pub-id-type="doi">10.4103/0974-2727.105592</article-id><article-categories><subj-group subj-group-type="heading"><subject>How I do it?</subject></subj-group></article-categories><title-group><article-title>Rapid Identification and Drug Susceptibility Testing of <italic>Mycobacterium tuberculosis</italic>: Standard Operating Procedure for Non-Commercial Assays: Part 1: Microscopic Observation Drug Susceptibility Assay v2.4.12</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Sarman</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Kumar</surname><given-names>Parveen</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Shreya</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mumbowa</surname><given-names>Francis</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Anandi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Durier</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Laboratory Medicine, Division of Clinical Microbiology, All India Institute of Medical Sciences, New Delhi, India</aff><aff id="aff2"><label>2</label>Department of Medical Microbiology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda</aff><aff id="aff3"><label>3</label>Department of Biochemistry and Microbiology, Ghent University, Belgium</aff><aff id="aff4"><label>4</label>Culture and Drug Susceptibility Testing Subgroup, New Diagnostic Working Group, STOP TB Partnership, Geneva, Switzerland</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Prof. Sarman Singh, <email xlink:href="sarman_singh@yahoo.com">sarman_singh@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Dec</season><year>2012</year></pub-date><volume>4</volume><issue>2</issue><fpage>101</fpage><lpage>111</lpage><permissions><copyright-statement>Copyright: &#x000a9; Journal of Laboratory Physicians</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Multidrug-resistant tuberculosis is an increasing public health concern in many parts of the world, especially in low-income countries, where most cases occur. Traditional mycobacteria culture and drug susceptibility testing (DST) is either time-consuming or expensive and for that reason uptake of these technologies has remained limited in many resource-constrained settings. However, several non-commercial culture and DST methods that do not require sophisticated infrastructure and techniques have been developed. One such method is the microscopic observation drug susceptibility assay (MODS). In this method microcolonies that form in the liquid culture medium after specimen inoculation to drug-free and drug-containing micro-wells are detected by visual observation with a simple inverted microscope. The identification and drug susceptibility results can be obtained in 7-15 days. This standard operating procedure document has been developed through the culture and DST subgroup of the STOP TB Partnership, New Diagnostic Working Group. It is intended for laboratories that would want to use or already using this rapid non-commercial method for culture identification and DST of <italic>Mycobacterium tuberculosis</italic>, notably in resource-constraint settings in Asia and Africa.</p></abstract><kwd-group><kwd>Tuberculosis</kwd><kwd>rapid</kwd><kwd>drug susceptibility testing</kwd><kwd>Stop-TB</kwd><kwd>Training</kwd></kwd-group></article-meta></front><body><sec id="sec1-1"><title>INTRODUCTION</title><sec id="sec2-1"><title>Scope</title><p>This standard operating procedure (SOP) document has been specially compiled for implementation of the non-commercial culture and drug susceptibility testing (DST) methods endorsed by New Diagnostic Working Group (NDWG)-STOP TB Partnership (WHO) for laboratory network performing the rapid non-commercial rapid culture identification and DST for <italic>Mycobacterium tuberculosis</italic> and intended for the use of Tuberculosis (TB) Diagnostic Laboratories, located in various Asian countries. It is also intended as a companion to the TB laboratory training manuals.</p><p>This SOP describes the procedure for the microscopic observation drug susceptibility assay (MODS), from the preparation of reagents and decontamination of the biological specimen, to the detection of mycobacterial growth and interpretation of the direct drug susceptibility results. It is a manual liquid mycobacterial culture method utilizing microscopic observation for detection of <italic>M. tuberculosis</italic> and DST. It can be performed as direct or indirect tests, for rapid screening of patients suspected of having multidrug-resistant tuberculosis (MDR-TB). Using an inverted microscope, microcolonies can be detected in a median of 7 days, much earlier than macroscopic colony growth can be seen on solid medium.</p><p>As suspensions with viable, infectious bacteria are handled, strict compliance with safety and protection measures is mandatory. The procedure must be carried out in a laboratory meeting the WHO standards for biosafety level 2 with access restricted to authorized personnel only.</p></sec><sec id="sec2-2"><title>Purpose</title><p>The purpose of this SOP is to rapidly provide clinicians with information about the patients suspected to have multidrug resistant (MDR) <italic>M. tuberculosis</italic> for proper clinical management.</p></sec><sec id="sec2-3"><title>Personnel qualifications</title><p>The test performer should be having a diploma in laboratory technologies and preferably university graduate in biological sciences with sufficient experience.</p><sec id="sec3-1"><title>Medical fitness</title><p>In accordance with national laws and practices, arrangements should be made for appropriate health surveillance of TB laboratory workers:</p><p><list list-type="bullet"><list-item><p>Before enrolment in the TB laboratory</p></list-item><list-item><p>At regular intervals thereafter, annually or bi-annually</p></list-item><list-item><p>After any biohazard incident</p></list-item><list-item><p>In case of onset of TB symptoms</p></list-item></list>
</p><p>All cases of disease or death identified in accordance with national laws and/or practice as resulting from occupational exposure to biological agents shall be notified to the competent authority.</p></sec><sec id="sec3-2"><title>Education and training</title><p>Personnel are required to be knowledgeable of the procedures in this SOP. Documentation of training and familiarization with this SOP can be found in the training file for each employee.</p><p>The laboratory staff shall confirm (i.e., documentation in the training file of familiarization with the SOP) that they can properly perform the procedure before commencing work. Education and training must be given on the following topics:</p><p>
<list list-type="bullet"><list-item><p>Potential risks to health (symptoms of TB disease and transmission)</p></list-item><list-item><p>Precautions to be taken to minimize aerosol formation and prevent exposure</p></list-item><list-item><p>Hygiene requirements</p></list-item><list-item><p>Wearing and use of protective equipment and clothing</p></list-item><list-item><p>Handling of potentially infectious materials</p></list-item><list-item><p>Laboratory design, including airflow conditions</p></list-item><list-item><p>Use of biological safety cabinets (BSC) (operation, identification of malfunctions, maintenance)</p></list-item><list-item><p>Use of autoclaves, incubators (operation, identification of malfunctions, maintenance)</p></list-item><list-item><p>Prevention of incidents and steps to be taken by workers in the case of incidents (biohazard incidents, chemical, electrical and fire hazards)</p></list-item><list-item><p>Good laboratory practice and good microbiological techniques</p></list-item><list-item><p>Organization of work flow and procedures</p></list-item><list-item><p>Waste management</p></list-item><list-item><p>Importance of laboratory results for patient management</p></list-item><list-item><p>Importance of laboratory results for the national TB programme</p></list-item><list-item><p>Training shall be given before a staff member takes up his/her post</p></list-item><list-item><p>Repeat training periodically, preferably every year</p></list-item></list>
</p></sec></sec><sec id="sec2-4"><title>Bio-safety precautions in tuberculosis laboratory</title><p>TB laboratory has all the major facility requirements for handling <italic>M. tuberculosis</italic> safely, and involves minimum risk to the laboratory personnel if they take proper precautions, and employ proper techniques described in these SOPs. Laboratory safety involves all the procedures and methods one needs to follow to minimize the risks of laboratory acquired infections. Use of laboratory is limited to trained TB laboratory personnel.</p><sec id="sec3-3"><title>Biological safety cabinets</title><p>
<list list-type="bullet"><list-item><p>Switch ON the safety cabinets for at least 30 min before use. Note that the reading on the mini gauge pressure is satisfactory.</p></list-item><list-item><p>Wear double pair of gloves, every time you work inside the cabinet.</p></list-item><list-item><p>Biosafety cabinets need to be cleaned with 5% phenolic or 1% hypochlorite solution before work.</p></list-item><list-item><p>Keep disposal bin/vessel with 5% phenolic or 5% hypochlorite disinfect inside the cabinet at right side corner.</p></list-item><list-item><p>Wipes of Gauge-cloth soaked in 5% phenolic or 5% hypochlorite, should be readily available inside the cabinet.</p></list-item><list-item><p>Arrange all un-infected material required towards left side.</p></list-item><list-item><p>All the processed samples need to be arranged right side.</p></list-item><list-item><p>Do not process more than six specimens at a time, inside the cabinet.</p></list-item><list-item><p>After completion of work, wipe off the surface with 5% phenolic solution, and discard all wipes in biohazard bags, or in disposal container meant for infectious materials.</p></list-item><list-item><p>Discard off the outer glove, too, inside the bio-safety cabinet.</p></list-item><list-item><p>Wipe off inner glove with disinfectant before touching anything else in the laboratory.</p></list-item></list>
</p></sec><sec id="sec3-4"><title>Waste disposal and handling</title><p>All infectious waste should be discarded in the bio-safety disposal bin. All infectious solid waste-wipes, swabs, plastic, paper towels, gauze pads, gloves, etc., should be placed inside the double autoclave bags, sealed with autoclave tape and sterilized at 121&#x000b0;C for 30 min in the autoclave.</p><p>Liquid waste, in the steel discarding bins, should be disinfected in 5% phenol for at least 1 h, before sealing the caps and autoclaved at 121&#x000b0;C for 30 min.</p></sec><sec id="sec3-5"><title>Accidents and spillages</title><p>
<list list-type="roman-lower"><list-item><p><bold>Spills inside biological safety cabinets</bold></p><p>All workers using the bio-safety cabinets should keep absorbent materials (gauge cloth/adsorbent sheet) and 5% phenol within the cabinet.</p><p>
<list list-type="bullet"><list-item><p>Alert all people in lab of immediate area of in the event of spill</p></list-item><list-item><p>Spread 5% phenol soaked wipe immediately, while the BSC continues to operate. Wait for 15-20 min</p></list-item><list-item><p>Use paper towels to wipe up the spill, working from the edges into the center</p></list-item><list-item><p>Decontaminate equipment: Items that are not readily or easily surface decontaminated should be carefully placed into autoclave bags and removed for further treatment (e.g., decontamination by autoclaving)</p></list-item><list-item><p>Contaminated gloves and clothes (sleeves are most likely to be contaminated); remove and decontaminate the lab coat by autoclaving or soaking in decontaminant</p></list-item></list>
</p></list-item><list-item><p><bold>Spills outside containment room in the biological safety cabinets</bold></p><p>Spills on equipment (such as vortex, centrifuge, incubator, refrigerator etc), laboratory benches, walls, or floors:</p><p>
<list list-type="bullet"><list-item><p>Immediately indicate to all personnel working in the lab, and evacuate for 1 h to allow dissipation of aerosols created by the spill (negative air pressure system would clear the aerosols)</p></list-item><list-item><p>Leave the BSC operating and cultures inside cabinet</p></list-item><list-item><p>Leave the containment facility following exit procedures</p></list-item><list-item><p>Close laboratory doors and post-warning signs to prevent others from entering the laboratory</p></list-item><list-item><p>Thoroughly wash hands and other apparently contaminated areas with soap and water. Put on clean disposable gloves</p></list-item><list-item><p>If personal clothing is contaminated, remove all outer clothing and place it in the autoclave or container for autoclaving. Put on clean garments</p></list-item><list-item><p>Upon returning to the laboratory wear the N95 mask, fresh lab coat and double pair gloves to start decontamination, cover the spill area with paper towels soaked in 5% Phenol solution or 1:10 dilution of 20% bleach (freshly prepared), or 70% ethanol solution (do not pour decontamination solution directly onto the spill in order to avoid additional release of aerosols)</p></list-item><list-item><p>Let stand for 20 min then wipe up with paper towels</p></list-item><list-item><p>Wipe up the spill with the soaked paper towels and place the used towels in an autoclave bag and autoclave</p></list-item><list-item><p>Place gloves and paper towels in autoclave bag and autoclave</p></list-item><list-item><p>Spill inside the centrifuge bucket/tube: Always use the aerosol containment cups for centrifuging. Always open the centrifuge buckets inside the bio-safety cabinet. Autoclave the buckets</p></list-item><list-item><p>Wash hands and other apparently contaminated areas again with soap and water</p></list-item></list>
</p></list-item><list-item><p><bold>Don't</bold></p><p>
<list list-type="bullet"><list-item><p>Eating, drinking, smoking, applying cosmetics, use of mobile phones, or applying contact lenses in the TB laboratory</p></list-item><list-item><p>Do not allow unauthorized personnel to enter the TB laboratory</p></list-item><list-item><p>Mouth pipetting</p></list-item><list-item><p>Crowding of lab with material that is not required inside</p></list-item></list>
</p></list-item></list>
</p></sec></sec></sec><sec id="sec1-2"><title>PROCEDURE</title><sec id="sec2-6"><title>Principle</title><p>MODS a liquid culture based test that detects <italic>M. tuberculosis</italic> and assesses isoniazid (INH) and rifampicin (RIF) susceptibility directly from samples. It is a tissue culture plate based assay which uses oleic acid dextrose catalase (OADC) enriched Middlebrook 7H9 liquid medium supplemented with antibiotic mixture polymyxin, amphotericin, nalidixic acid, trimethoprim, azlocillin (PANTA).</p><p>The principle of MODS is based on three characteristics:</p><p>
<list list-type="bullet"><list-item><p><italic>M. tuberculosis</italic> grows faster in liquid medium than solid medium.</p></list-item><list-item><p>Characteristic cord formation can be visualized microscopically in liquid medium at any stage in viable cells and this differentiates it from NTM.</p></list-item><list-item><p>Incorporation of drugs permits rapid and direct DST concomitantly with detection of bacterial growth.</p></list-item></list>
</p><p>The simplicity of the technique, the greater sensitivity of liquid over solid media culture for TB detection, the specificity of the characteristic growth of <italic>M. tuberculosis</italic>, the evaluation of drug susceptibility in a short timescale and the low cost of reagents are the major advantages of the method.</p></sec><sec id="sec2-7"><title>Requirements</title><sec id="sec3-6"><title>Sample</title><p>
<list list-type="bullet"><list-item><p>Clinical sample for direct MODS.</p></list-item><list-item><p>Pure cultures of acid - fast bacilli grown on solid media/liquid medium, for indirect MODS.</p></list-item></list>
</p></sec><sec id="sec3-7"><title>Equipment and materials</title><p>
<list list-type="bullet"><list-item><p>BSC, class II, annually certified</p></list-item><list-item><p>Inverted light microscope</p></list-item><list-item><p>Incubator set at 37&#x000b0;C</p></list-item><list-item><p>Autoclave</p></list-item><list-item><p>Weighing balance</p></list-item><list-item><p>Refrigerator/freezer</p></list-item><list-item><p>Vortex</p></list-item><list-item><p>Micropipettes (1000 &#x003bc;l, 200 &#x003bc;l, and 20 &#x003bc;l)</p></list-item></list>
</p></sec><sec id="sec3-8"><title>Reagents and solutions preparation</title><p>
<list list-type="bullet"><list-item><p>Sodium hydroxide (NaOH) (Merck, MB1M61-321)</p></list-item><list-item><p>Tri-sodium citrate (Na <sub>3</sub> C <sub>6</sub> H <sub>5</sub> O <sub>7</sub>&#x00387;2H <sub>2</sub> O) (Fisher Scientific, 14005)</p></list-item><list-item><p>N-acetyl-l-cysteine (NALC) (C <sub>5</sub> H <sub>9</sub> NO <sub>3</sub> S) (Central Drug House, 011011)</p></list-item><list-item><p>Potassium dihydrogen phosphate (KH <sub>2</sub> PO <sub>4</sub> ) (Merck, 1048729025)</p></list-item><list-item><p>Di-sodium hydrogen phosphate anhydrous (Na <sub>2</sub> HPO <sub>4</sub> ) (Merck, MG7M571666)</p></list-item><list-item><p>Di-methyl sulfoxide (Sigma, 472301)</p></list-item><list-item><p>Glycerol Reagent Grade (Merck, 356350)</p></list-item><list-item><p>Tween-80 (Merck, SI9S590405).</p></list-item></list>
</p></sec><sec id="sec3-9"><title>Drugs</title><p>
<list list-type="bullet"><list-item><p>RIF (Sigma, ref. R7382)</p></list-item><list-item><p>INH (Sigma, ref. I3377).</p></list-item></list>
</p></sec><sec id="sec3-10"><title>Media</title><p>
<list list-type="bullet"><list-item><p>Middlebrook 7H9 broth (ref. 271310-500 g-Becton Dickinson) to be supplemented with glycerol, OADC (ref. 211886 - 10&#x000d7; 20 ml - Becton Dickinson) and PANTA (ref. B4345114 BD Diagnostic Systems).</p></list-item></list>
</p></sec><sec id="sec3-11"><title>Other consumables</title><p>
<list list-type="bullet"><list-item><p>Sterile micropipette tips</p></list-item><list-item><p>Sterile microcentrifuge tubes</p></list-item><list-item><p>Screw cap glass tubes</p></list-item><list-item><p>Sterile plastic tubes</p></list-item><list-item><p>24-well plates</p></list-item><list-item><p>Storage vials</p></list-item><list-item><p>Millipore filters, 0.2 &#x003bc;m filters</p></list-item><list-item><p>Parafilm or Zip lock bags</p></list-item><list-item><p>50 ml polypropylene centrifuge tubes.</p></list-item></list>
</p></sec></sec><sec id="sec2-8"><title>Preparation</title><sec id="sec3-12"><title>NaOH-NALC solution preparation</title><p>4% NaOH and 2.9% Na citrate solution with 0.5% NALC (decontamination/processing solution)</p><p>
<list list-type="bullet"><list-item><p>4% Sodium hydroxide</p></list-item><list-item><p>2.9% Sodium citrate dehydrate or 2.6% sodium citrate anhydrous</p></list-item><list-item><p>NALC</p></list-item></list>
</p><p>The sodium hydroxide and sodium citrate may be mixed as given in <xref ref-type="table" rid="T1">Table 1</xref>, sterilized and stored in sterile screw cap bottle for use. After NALC has been added, the prepared volume of digestant must be used within 24 h, as NALC loses mucolytic activity on standing for long. For preparation of NaOH-NALC solution [<xref ref-type="table" rid="T1">Table 1</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Preparation of sodium hydroxide-N-acetyl-l-cysteine buffer</p></caption><graphic xlink:href="JLP-4-101-g001"/></table-wrap></sec><sec id="sec3-13"><title>Preparation of 0.067 M phosphate buffer (pH 6.8)</title><p>
<list list-type="alpha-upper"><list-item><p>Disodium phosphate: Dissolve 9.47 g of anhydrous Na <sub>2</sub>&#x00387;HPO <sub>4</sub> in 1 l of distilled water (DW).</p></list-item><list-item><p>Mono-potassium phosphate: Dissolve 9.07 g of KH <sub>2</sub> PO <sub>4</sub> in 1 l of DW.</p><p>
<list list-type="bullet"><list-item><p>Mix 950 ml of solution A with 950 ml of solution B and stir; keep back 50 ml of each solution to adjust pH if necessary</p></list-item><list-item><p>If final buffer requires pH adjustments, add solution (A) to raise the pH or solution (B) to lower it</p></list-item></list>
</p></list-item></list>
</p></sec></sec><sec id="sec2-9"><title>Preparation of Middlebrook 7H9</title><p><inline-graphic xlink:href="JLP-4-101-g002.jpg"/></p><p>
<list list-type="bullet"><list-item><p>Dissolve 5.9 g of 7H9 medium powder in 900 ml of sterile DW containing 3.1 ml of glycerol and 1.25 g of casitone.</p></list-item><list-item><p>Mix until completely dissolved, heat if required.</p></list-item><list-item><p>Cool and divide the sterile medium into 4.5 ml aliquots in sterile screw capped glass tubes for sample preparation and internal controls. Also aliquot 10.8 ml in sterile screw capped glass tubes for antibiotic solutions.</p></list-item><list-item><p>Autoclave at 121&#x000b0;C for 20 min*</p></list-item><list-item><p>Incubate at 37&#x000b0;C for 48 h to verify sterility (lack of turbidity).</p></list-item><list-item><p>Store at 2-8&#x000b0;C with cap tightly closed for up to 1 month. (Note: Each sputum sample and internal controls require one tube containing 4.5 ml of 7H9 medium.)</p></list-item></list>
</p><sec id="sec3-14"><title>Final 7H9-OADC and 7H9-OADC-PANTA medium preparation</title><p>
<list list-type="roman-lower"><list-item><p><bold>7H9-OAD</bold></p><p>
<list list-type="bullet"><list-item><p>OADC: Enrichment supplement (oleic acid, albumin, dextrose, and catalase): Commercial preparation comes ready for use. OADC should be used at 10% in 7H9 medium.</p></list-item><list-item><p>*You can add the OADC after autoclave of the 7H9 medium and cooling down. Add 100 ml OADC to 900 ml of 7H9 medium</p></list-item></list>
</p></list-item><list-item><p><bold>7H9-OADC-PANTA</bold></p><p>
<list list-type="bullet"><list-item><p>PANTA: Antibiotic supplement used to minimize contamination of MODS culture by oral flora micro-organisms not killed during the decontamination process. The BBL MGIT PANTA vial contains a lyophilized mixture of antimicrobial agents</p></list-item><list-item><p>Reconstitute a lyophilized vial of BBL MGIT PANTA with 3 ml of sterile DW [<xref ref-type="table" rid="T2">Table 2</xref>].Final media preparation should only be performed on the day of using 7H9 medium, OADC and PANTA</p></list-item></list>
</p></list-item></list>
</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Polymyxin, amphotericin, nalidixic acid, trimethoprim, azlocillin concentration after reconstitution</p></caption><graphic xlink:href="JLP-4-101-g003"/></table-wrap></sec><sec id="sec3-15"><title>Set out</title><p>
<list list-type="bullet"><list-item><p>For every sample: 1 Tube with 4.5 ml 7H9 medium +0.5 ml OADC for every sample/or 5 ml 7H9-OADC already prepared [<xref ref-type="fig" rid="F1">Figure 1</xref>]</p></list-item><list-item><p>For the medium control (MC) column: 1 Tube with 4.5 ml 7H9 medium for every plate +0.5 ml OADC/or 5 ml 7H9-OADC already prepared</p></list-item><list-item><p>For the quality control (QC): 2 Tubes with 4.5 ml 7H9 medium +0.5 ml OADC/or 5 ml 7H9-OADC already prepared (1 for H <sub>37</sub> Rv and 1 for MDR strain)</p></list-item><list-item><p>For drug solution preparation - 2 tubes/sterile micro centrifuge tube (MCT's) with 990 &#x003bc;l 7H9-OADC [<xref ref-type="table" rid="T3">Table 3</xref>].</p></list-item><list-item><p>Reconstitute PANTA in 3 ml sterile DW and add 0.1 ml to each sample tube and to the MC tubes (7H9-OADC-PANTA: Total volume = 5.1 ml).</p></list-item></list>
</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Preparation of medium tubes</p></caption><graphic xlink:href="JLP-4-101-g004"/></fig><p>The final volume of 7H9-OADC and 7H9-OADC-PANTA required will vary according to the number of plates being set-up. (Note: Complete medium 7H9-OADC-PANTA is used for samples and MCs. Use 7H9-OADC without PANTA for QCs and for antibiotic solution preparation.)</p></sec></sec><sec id="sec2-10"><title>Preparation of drug stock and dilution</title><sec id="sec3-16"><title>For preparation of drug stock and drug dilutions</title><p>
<list list-type="bullet"><list-item><p>Take 990 &#x003bc;l of 7H9-OADC in each of the two micro-centrifuge tubes (MCT-1 and MCT-2)</p></list-item><list-item><p>Add 10 &#x003bc;l of INH stock (0.4 mg/ml) solution to MCT-1 (total volume 1000 &#x003bc;l); mix well. This gives working concentration (4 &#x003bc;g/ml) of INH.</p></list-item><list-item><p>Add 10 &#x003bc;l on RIF stock (1 mg/ml) solution to MCT-2 (total volume 1000 &#x003bc;l); mix well. This gives working concentration (10 &#x003bc;g/ml) of RIF.</p></list-item><list-item><p>The tubes are ready for further use [Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>].</p></list-item></list>
</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Preparation of drug dilutions to be used in medium</p></caption><graphic xlink:href="JLP-4-101-g005"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Preparation of drug stock</p></caption><graphic xlink:href="JLP-4-101-g006"/></table-wrap></sec></sec><sec id="sec2-11"><title> Test procedure</title><sec id="sec3-17"><title>Quality control</title><p>Well characterized TB strains: One fully susceptible strain (H<sub>37</sub>Rv standard strain) and one MDR strain (if possible) are run as QC. For each batch of MODS plate being set-up 1 batch of QC is run. If the controls do not show the expected pattern, the results of samples plated on that day are not valid.</p><p>
<list list-type="roman-lower"><list-item><p><bold>Requirements</bold></p><p>
<list list-type="bullet"><list-item><p>Susceptible control strain</p></list-item><list-item><p>MDR control strain</p></list-item><list-item><p>7H9-OADC, 5 ml</p></list-item><list-item><p>10% sterile Tween 80, 40 &#x003bc;l</p></list-item><list-item><p>Sterile DW, 10 ml</p></list-item></list>
</p></list-item><list-item><p><bold>Procedure</bold></p><p>
<list list-type="bullet"><list-item><p>Mix 10 ml sterile DW and 40 &#x003bc;l of 10% sterile Tween 80 in a sterile tube (final Tween 80 concentration = 0.04%)</p></list-item><list-item><p>Using a sterile loop, harvest several colonies of mycobacteria and place in a sterile tube containing 100 &#x003bc;l water-Tween 80 solution and sterile glass beads (do not scrape the medium)</p></list-item><list-item><p>Cap tube tightly and vortex for 2 - 3 min; (till there are no visible clumps)</p></list-item><list-item><p>Let it stand for 5 min</p></list-item><list-item><p>Open tube and add 3 ml of water-Tween 80; cap tightly and vortex again for 20 s (till suspension has uniform turbidity). Let it stand for 30 min</p></list-item><list-item><p>Transfer the supernatant to another sterile tube using a pipette</p></list-item><list-item><p>Adjust turbidity to McFarland Scale 1 (approximately 3 &#x000d7; 10<sup>8</sup> CFU/ml) with 0.04% water-Tween 80 solution</p></list-item><list-item><p>The growth suspension can be used up to 4 weeks (keep at 2-8&#x000b0;C)</p></list-item></list>
</p></list-item><list-item><p><bold>Preparation of inoculum</bold></p><p>
<list list-type="bullet"><list-item><p>Mix 5 &#x003bc;l of each McFarland 1 (McF 1) control strain suspension with 5 ml of 7H9-OADC medium. This is the QC suspension ready for plating. The culture suspension for both susceptible strain and MDR strains is prepared separately for plating, as shown in <xref ref-type="fig" rid="F2">Figure 2</xref></p></list-item></list>
</p></list-item></list>
</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Preparation of inoculum tubes for direct microscopic observation drug susceptibility assay</p></caption><graphic xlink:href="JLP-4-101-g007"/></fig></sec><sec id="sec3-18"><title>Indirect MODS from culture medium</title><p>Pure culture of acid - fast bacilli grown on solid medium is used for indirect MODS. Confirm the growth as <italic>M. tuberculosis</italic> using MPT-64, PNB or any other standard methods being practiced in the local laboratory.</p><p>
<list list-type="roman-lower"><list-item><p><bold>Requirements</bold></p><p>
<list list-type="bullet"><list-item><p>7H9-OADC-PANTA, 5 ml</p></list-item><list-item><p>10% sterile Tween 80, 40 &#x003bc;l</p></list-item></list>
</p></list-item><list-item><p><bold>Procedure</bold></p><p>
<list list-type="bullet"><list-item><p>Mix 10 ml sterile DW and 40 &#x003bc;l of 10% sterile Tween 80 in a sterile tube (final Tween 80 concentration = 0.04%)</p></list-item><list-item><p>Using a sterile loop, harvest several colonies of Mycobacteria and place in a sterile tube containing 100 &#x003bc;l water-Tween 80 solution and sterile glass beads (do not scrape the medium)</p></list-item><list-item><p>Cap tube tightly and vortex for 2-3 min; (till there are no visible clumps)</p></list-item><list-item><p>Let it stand for 5 min</p></list-item><list-item><p>Open tube and add 3 ml of water-Tween 80; cap tightly and vortex again for 20 s (till suspension has uniform turbidity). Let it stand for 30 min</p></list-item><list-item><p>Transfer the supernatant to another sterile tube using a pipette</p></list-item><list-item><p>Adjust turbidity to McFarland Scale 1 (approximately 3 &#x000d7; 10 <sup>8</sup> CFU/ml) with 0.04% water-Tween 80 solution. (Note: Preparation of McF 1 suspension involves manipulation of concentrated suspensions of mycobacteria and should only be carried out in a BSC)</p></list-item></list>
</p></list-item><list-item><p><bold>Preparation of inoculum</bold></p><p>
<list list-type="bullet"><list-item><p>Mix 5 &#x003bc;l of each McF 1 growth suspension with 5 ml of 7H9-OADC-PANTA medium. This is the final culture suspension ready for plating, as shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p></list-item></list>
</p></list-item></list>
</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Preparation of inoculum tubes for indirect microscopic observation drug susceptibility assay</p></caption><graphic xlink:href="JLP-4-101-g008"/></fig></sec><sec id="sec3-19"><title>For direct MODS from clinical sample</title><p>Clinical sample is used. Sample decontamination is must to avoid bacterial/fungal growth in plate being set-up. Decontamination is carried out using the sodium hydroxide-N-acetyl-l-cysteine (NaOH-NALC). NALC is a mucolytic agent; it must be added to the sterile NaOH-Na citrate solution on the day of use, as activity wanes, if stored for long. The sodium citrate in the NaOH solution prevents heavy metal ions that may be present from deactivating the NALC.</p><p>
<list list-type="roman-lower"><list-item><p><bold>Samples not requiring decontamination</bold></p><p>The following specimens usually do not need decontamination when aseptically collected into sterile containers:</p><p>
<list list-type="bullet"><list-item><p>Spinal or other internal body fluids but should be collected aseptically</p></list-item><list-item><p>Bone marrow aspirate if collected aseptically</p></list-item><list-item><p>Pus from closed cold abscesses such as fine needle aspiration cytology (FNAC) material</p></list-item><list-item><p>Surgically resected specimens (excluding autopsy material)</p></list-item><list-item><p>Material obtained from pleural, liver and lymph nodes as well as biopsies (if not fistulised).</p></list-item></list>
</p></list-item><list-item><p><bold>Requirements for one sample</bold></p><p>
<list list-type="bullet"><list-item><p>NaOH-NALC solution, 3-5 ml</p></list-item><list-item><p>0.067 M phosphate buffer (pH 6.8), 45 ml</p></list-item><list-item><p>7H9-OADC-PANTA, 5.1 ml</p></list-item></list>
</p></list-item><list-item><p><bold>Procedure for decontamination of sputum using N-acetyl-l-cysteine sodium hydroxide (NaOH-NALC): Modified Petroff's Method</bold></p><p>The mucolytic agent, NALC is used for rapid digestion of sputum this enables the decontaminating agents like NaOH, to be used at a lower concentration (in sputum).</p><p>
<list list-type="bullet"><list-item><p>Transfer a maximum volume of 3-5 ml of specimen to a sterile 50 ml centrifuge tube (aerosol free and graduated).</p></list-item><list-item><p>Add equal volume of NALC-NaOH-Na citrate solution aseptically.</p></list-item><list-item><p>Mix the control for approx. 20 s on vortex mixture. Be sure to invert the tube so that NALC-NaOH comes in contact with the entire surface of the tube.</p></list-item><list-item><p>Allow the mixture to stand at room temperature for 15 min to decontaminate the specimen with occasional gentle shaking.</p></list-item><list-item><p>Neutralize the mixture by adding sterile phosphate buffer (pH 6.8) up to the 50 ml in the tube and recap it.</p></list-item><list-item><p>Centrifuge the tube at 3000g for 15 min.</p></list-item><list-item><p>Decant the supernatant.</p></list-item></list>
</p><p>Sputum &#x02192; NAOH/NALC decontamination &#x02192; re-suspend the pellet in 2 ml 7H9-OADC-PANTA (900 &#x003bc;l will be plated).</p></list-item><list-item><p><bold>Inoculum preparation</bold></p><p>Using 7H9-OADC-PANTA (from the tube containing 5.1 ml), re-suspend the sample pellet in a total volume of 2 ml in the centrifuge tube with a Pasteur pipette; mix well.</p><p>
<list list-type="bullet"><list-item><p>Remove 1 ml of sample suspension and store in a storage vial at 2-8&#x000b0;C as a backup.</p></list-item><list-item><p>Add the remaining 1 ml of sample suspension to the tube with the remaining 7H9-OADC-PANTA; mix well. This is the final sample suspension ready for plating.</p></list-item></list>
</p></list-item></list>
</p></sec></sec><sec id="sec2-12"><title> Medium control</title><p>These are the wells with 7H9-OADC-PANTA culture medium but without sample and these are run on every plate. If any mycobacterial colonies are observed in any well, it indicates cross-contamination.</p><p>The entire plate should be discarded and backup samples reprocessed, if available, or new samples requested. Prepare 5.1 ml of 7H9-OADC-PANTA. This is the final solution ready for plating.</p></sec><sec id="sec2-13"><title>MODS method-Setting up the plate</title><sec id="sec3-20"><title>For sample/culture</title><p>
<list list-type="bullet"><list-item><p>Take a 24 well plate (for upto five samples).</p></list-item><list-item><p>Mark the wells on plate: Growth control (GC), MC, INH, RIF, as shown in [<xref ref-type="fig" rid="F4">Figure 4</xref>].</p></list-item><list-item><p>Dispense 900 &#x003bc;l of culture/sample suspension in all 4 wells of column 1 to 6 sequentially, except column 4.</p></list-item><list-item><p>Dispense 900 &#x003bc;l of MC in all 4 wells of column 4.</p></list-item><list-item><p>Dispense 100 &#x003bc;l of working solution (WS) of INH in all wells of row C from MCT-1</p></list-item><list-item><p>Dispense 100 &#x003bc;l of WS of RIF in all wells of row D from MCT-2.</p></list-item><list-item><p>Add 100 &#x003bc;l remaining MC to rest of all the wells of row A and B to make final volume of 1 ml in each well.</p></list-item><list-item><p>Close the plate with its lid and seal it with parafilm from all sides or zip lock bag.</p></list-item><list-item><p>Incubate at 37&#x000b0;C. (Note: If more than five samples or cultures are being tested use another plate. It is advisable not to test samples/cultures on the same plate on which QC strains are being run to avoid cross-contamination.)</p></list-item></list>
</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Setting up of microscopic observation drug susceptibility assay plate for sample/culture</p></caption><graphic xlink:href="JLP-4-101-g009"/></fig></sec><sec id="sec3-21"><title>For quality control</title><p>For each batch 1 set of separate QC (1 H <sub>37</sub> Rv and 1 MDR) plate is run.</p><p>
<list list-type="bullet"><list-item><p>Take a 24 well plate</p></list-item><list-item><p>Mark the wells on plate: H <sub>37</sub> Rv, MC, MDR, INH and RIF, as shown in <xref ref-type="fig" rid="F5">Figure 5</xref></p></list-item><list-item><p>Dispense 900 &#x003bc;l of suspension of H <sub>37</sub> Rv in all four wells of column 1</p></list-item><list-item><p>Dispense 900 &#x003bc;l of suspension of MDR in all four wells of column 3</p></list-item><list-item><p>Dispense 900 &#x003bc;l of MC in all 4 wells of column 2</p></list-item><list-item><p>Dispense 100 &#x003bc;l of WS of INH in wells 1-3 of row C from MCT-1</p></list-item><list-item><p>Dispense 100 &#x003bc;l of WS of RIF in wells 1-3 of row D from MCT-2</p></list-item><list-item><p>Add 100 &#x003bc;l remaining MC to rest of all the wells of row A and B to make final volume of 1 ml in each well</p></list-item><list-item><p>Close the plate with its lid and seal it with parafilm from all sides or place in a zip lock bag</p></list-item><list-item><p>Incubate at 37&#x000b0;C</p></list-item></list>
</p><fig id="F5" position="float"><label>Figure 5</label><caption><p>Setting up of microscopic observation drug susceptibility assay plate for quality control strains</p></caption><graphic xlink:href="JLP-4-101-g010"/></fig></sec></sec><sec id="sec2-14"><title>Plate reading</title><p>A positive result is defined as two or more colony forming units (&#x0003e;2 cfu) in each of the two drug-free wells.</p><p>Positive control: If positive controls do not grow in the expected pattern, the results of samples plated on the same day are not valid.</p><p>Negative control: If any mycobacterial colonies are observed in any media control well, it indicates cross-contamination, results of samples plated on the same day are not valid.</p><sec id="sec3-22"><title>Plate reading of GC/drug-free wells </title><p>
<list list-type="bullet"><list-item><p>Start examining drug-free wells on day 5.</p></list-item><list-item><p>Early mycobacterial growth looks like small curved commas or spirals (days 5-9).</p></list-item><list-item><p>Confirm the growth as <italic>M. tuberculosis</italic> using MPT-64, PNB or any other standard method. Reading should be followed only if the growth is MTB (not required in case of indirect MODS).</p></list-item><list-item><p>Colony formation usually progresses to cords, and later more irregular tangled growth.</p></list-item><list-item><p>If two or more colonies (&#x0003e;2 cfu) are detected in each of the two wells, the result is positive.</p></list-item><list-item><p>If results are negative on day 5, continue reading drug-free wells daily (or on alternate days according to laboratory workload) until &#x0003e;2 cfu are observed in each of the two wells.</p></list-item><list-item><p>When a positive result is observed, read the INH and RIF containing wells on the same day.</p></list-item><list-item><p>If no growth is observed by day 15, repeat reading on day 18 and day 21. If results are still negative on day 21 the final result is negative.</p></list-item><list-item><p>If only 1 cfu appears in either drug-free well, or in both, the result is &#x0201c;indeterminate&#x0201d;. [<xref ref-type="table" rid="T5">Table 5</xref>]</p></list-item></list>
</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Reading and interpretation of drug.free wells</p></caption><graphic xlink:href="JLP-4-101-g011"/></table-wrap></sec></sec><sec id="sec2-15"><title>Before final results can be considered valid, the QC and MC wells must be examined and interpreted.</title><p>
<list list-type="bullet"><list-item><p>For initial readings, examine wells with the &#x000d7;10 microscope objective to search for early colony forms (&#x000d7;100 final magnification). For subsequent readings, use the &#x000d7;4 objective (&#x000d7;40 final magnification) to examine the entire contents of each well.</p></list-item><list-item><p>The culture medium does not become cloudy with growth of<italic>M. tuberculosis</italic>.</p></list-item><list-item><p>Growth in only one well, or less than 2 cfu in each of the two wells, should be considered an indeterminate result, and should prompt a request for a repeat sample and a search for evidence of cross-contamination.</p></list-item><list-item><p>Intervals between readings can be flexible to suit laboratory workload and schedule. (Notes: More frequent readings yield faster results.)</p></list-item></list>
</p></sec><sec id="sec2-16"><title>Reading of drug wells</title><p>
<list list-type="bullet"><list-item><p>On the same day that both drug-free wells have definite mycobacterial growth of &#x0003e;2 cfu, examine the INH- and RIF-containing wells.</p></list-item><list-item><p>If there is any growth of &#x0003e;2 cfu in a drug-containing well, the sample is resistant to that drug (at the concentration present); no growth means the sample is sensitive to the drug.</p></list-item><list-item><p>If there is positive growth in both INH- and RIF-containing wells, the sample is MDR.</p></list-item><list-item><p>Drug-containing wells should NOT be re-examined if the reading of drug-free well is identified as negative. (Notes: Growth may be less florid in the drug-containing well but the presence of &#x02265;;2 cfu indicates resistance (this is not a proportions-type test).)</p></list-item><list-item><p>Only very rarely is a single cfu detected in drug-containing wells (read at the correct time point), however if this is encountered the interpretation is indeterminate.</p></list-item><list-item><p>Growth in drug-containing wells should only be considered as indicating resistance if drug-free wells for the same sample have also shown growth [<xref ref-type="table" rid="T6">Table 6</xref>].</p></list-item></list>
</p><table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Reading and interpretation of drug wells (drug resistance)</p></caption><graphic xlink:href="JLP-4-101-g012"/></table-wrap><sec id="sec3-23"><title>Reading of medium control </title><p>
<list list-type="bullet"><list-item><p>All four wells in of MC should have no growth.</p></list-item><list-item><p>If any mycobacterial colonies are observed in any well, there has been cross-contamination. The entire plate should be discarded.</p></list-item><list-item><p>A search for potential sources of cross-contamination should occur and if the source is identified appropriate, remedial action should be taken.</p></list-item></list>
</p></sec><sec id="sec3-24"><title>Reading of quality control wells</title><p>
<list list-type="roman-lower"><list-item><p><bold>Drug-free wells</bold></p><p>
<list list-type="bullet"><list-item><p>All drug-free wells should have positive mycobacterial growth (&#x0003e;2cfu).</p></list-item><list-item><p>Absence of growth in all drug-free wells suggests that the medium does not support growth sample results are not valid. All samples plated out on the same day should be reprocessed with a new batch of medium.</p></list-item><list-item><p>If only one of the two positive control strains grows in drug-free wells, the strain that did not grow may not be viable. A fresh strain suspension should be used with re-testing.</p></list-item></list>
</p></list-item><list-item><p><bold>Drug-containing wells</bold></p><p>
<list list-type="bullet"><list-item><p>The drug-susceptible control strain should not grow in either of the drug-containing wells. Growth indicates incorrect (low) antibiotic concentrations or inadequate INH and/or RIF activity.</p></list-item><list-item><p>The drug-resistant control strain (1 MDR strain, or 2 mono-resistant strains) should grow in the drug-containing wells. Absence of growth indicates that the final INH and/or RIF concentrations are too high. ( Notes: Absence of control strain growth in all drug-free wells may also indicate strain non-viability. Consider use of fresh control strain preparations for re-testing.)</p></list-item><list-item><p>Reduced drug activity may be due to incorrect concentrations, or reduced potency related to improper handling or storage of original, undiluted, drug or drug stock solution.</p></list-item></list>
</p></list-item></list>
</p></sec></sec><sec id="sec2-17"><title>MODS results on different days</title><p>For interpretation of results, refer to <xref ref-type="fig" rid="F6">Figure 6</xref>.</p><fig id="F6" position="float"><label>Figure 6</label><caption><p>Demonstration of microscopic observation drug susceptibility assay results on different days of incubation, under different light settings. 7 days: Growth of mycobacterial cords on day 7, 10 days: Growth of mycobacterial cords on day 10. 15 days: Growth of mycobacterial cords on day 15</p></caption><graphic xlink:href="JLP-4-101-g013"/></fig></sec><sec id="sec2-18"><title>Plate disposal</title><p>
<list list-type="bullet"><list-item><p>Keep all plates sealed inside their original zip lock plastic bags and seal in an autoclave bag.</p></list-item><list-item><p>Autoclave at 121&#x000b0;C for 30 min.</p></list-item><list-item><p>Discard the sealed sterilized bags in the site designated for this purpose.</p></list-item></list>
</p></sec><sec id="sec2-19"><title>Quality assurance</title><p>The MODS method described in this SOP includes sterility checks for stock solutions and medium. The positive internal controls test medium and antibiotic solution function; the negative internal controls test for cross-contamination.</p></sec></sec><sec id="sec1-3"><title>FURTHER READING</title><p>
<list list-type="order"><list-item><p>Caviedes L, Moore DA. Introducing MODS: A low-cost, low-tech tool for high-performance detection of tuberculosis and multidrug resistant tuberculosis. Indian J Med Microbiol 2007;25:87-8.</p></list-item><list-item><p>Kent PT, Kubica GP. Public Health Mycobacteriology: A Guide for the Level III Laboratory. Washington, DC, Centres for Disease Control and Prevention, Atlanta US Government Printing Office; 1985. p. 207.</p></list-item><list-item><p>Coronel J, Roper M, Caviedes L, Moore D. MODS. A User Guide. Microscopic-Observation Drug-Susceptibility Assay, 2008. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.modsperu.org/MODS_user_guidepdf.V12.213012012">http://www.modsperu.org/MODS_user_guidepdf.V12.213012s012</ext-link> [Last Accessed on 2012 Feb 28].</p></list-item><list-item><p>Moore DA. Future prospects for the MODS assay in multidrug-resistant tuberculosis diagnosis. Future Microbiol 2007;2:97-101.</p></list-item><list-item><p>World Health Organization. Noncommercial culture and drug susceptibility testing methods for screening of patients at risk of multi drug resistant tuberculosis: Policy statement; July, 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/dots/laboratory/whopolicy_noncommercialculture_and_dstmethods_july10.pdf">http://www.who.int/tb/dots/laboratory/whopolicy_noncommercialculture_and_
dstmethods_july10.pdf</ext-link> [Last accessed on 2012 Nov 10].</p></list-item></list>
</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors would like to thank Dr. Alessandra Varga of FIND for her administrative support to this project, to Dr. David Moore for his technical inputs in the preparation and finalization of this SOP and all core members of the New Diagnostic Working Group (NDWG) for approving this project.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Culture and drug susceptibility testing subgroup,
Stop-TB Partnership, WHO &#x00026; FIND, Geneva, Switzerland</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group></back></article>